BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Moderna, Excision Launch HIV Trials Inspired by COVID-19 Pandemic

  Moderna invested heavily in mRNA technology to manufacture some 900 million doses of the COVID-19 vaccine. Now, the company has created an mRNA-based vaccine to prevent HIV.

  January 28, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Policy

  Post-marketing Study Problems Claim Sanofi-Regeneron Cervical Cancer sBLA

  The FDA had accepted the sBLA in September 2021 under priority review status.

  January 28, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake

  Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.

  January 28, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Don’t Count Out Omicron Sibling BA.2, and More COVID-19 News

  Researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark. For that and more COVID-19 news, continue reading.

  January 28, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  2021 Was Banner Year for VC Funding for Biopharma in the Bay State

  A new report showed the increased funding in 2021 mirrors national data that show accelerated financing in support of new therapies for multiple diseases, driven by COVID-19 concerns.

  January 28, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Lilly’s Olumiant Portfolio Takes a Pair of Hits as Lupus Program Discontinued

  Eli Lilly and Company announced that it was discontinuing the Phase III development program for Olumiant (baricitinib) in lupus.

  January 28, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  GSK and Verily’s Galvani Treats First RA Patient in Bioelectronics Study

  The company initiated the use of splenic nerve simulation last month as part of a small clinical trial at the NHS Greater Glasgow & Clyde Health Board in Scotland.

  January 28, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Taysha’s Promising Gene Therapy Results Marred by Patient’s Death

  Taysha said the data for TSHA-101 is the “first-ever to support the bicistronic vector approach in humans delivering both HEXA and HEXB genes in the endogenous ratio.”

  January 28, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Oxford Biomedica and Homology Medicines Strike a Win-Win Deal

  Oxford BioMedica and Homology Medicines have formed a symbiotic partnership to launch a full scope AAV manufacturing and innovation business.

  January 28, 2022

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Provention Gets Another Shot at Delaying Diabetes

  The resubmission follows a Type B pre-BLA resubmission meeting with the US Food and Drug Administration (FDA).

  January 28, 2022

   · 

  2 min read

   · 

  Hayley Shasteen